In vitro elution of ofloxacin from a bioabsorbable polymer

Nie, Lihong; Nicolau, David P.; Nightingale, Charles H.; Browner, Bruce D.; Quintiliani, Richard

doi:10.3109/17453679508995563

Cited by 34 publications

(19 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several previous in vitro and in vivo studies (1,6,17,25,28,30,32,39) have delineated the use of polymers in different chemistries (polylactides, copolymers of lactide and glycolide, polyanhydrides, and polycaprolactone) as systems for the delivery of various antibiotics. The same composites have uniformly given positive results for the treatment of experimental osteomyelitis (2,8,16,19,29,34,38).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Ciprofloxacin-Releasing Bioabsorbable Osteoconductive Bone Defect Filler for Treatment of Experimental Osteomyelitis Due to Staphylococcus aureus

Koort

Mäkinen

Suokas

et al. 2005

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The concept of local antibiotic delivery via biodegradable bone defect fillers with multifunctional properties for the treatment of bone infections is highly appealing. Fillers can be used to obliterate surgical dead space and to provide targeted local bactericidal concentrations in tissue for extended periods. Eventually, the osteoconductive component of the filler could guide the healing of the bone defect. The present experimental study was carried out to test this concept in a localized Staphylococcus aureus osteomyelitis model in the rabbit (n ‫؍‬ 31). A metaphyseal defect of the tibia was filled with a block of bone cement, followed by insertion of a bacterial inoculum. After removal of the bone cement and surgical debridement at 2 weeks, the defect was filled with a ciprofloxacin-containing (7.6% ؎ 0.1%, by weight) composite (treated-infection group) or with a composite without antibiotic (sham-treated group). Both a positive control group (untreated-infection group) and a negative control group were also produced.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Ciprofloxacin-Releasing Bioabsorbable Osteoconductive Bone Defect Filler for Treatment of Experimental Osteomyelitis Due to Staphylococcus aureus

Koort

Mäkinen

Suokas

et al. 2005

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…An ideal antibiotics delivery system should (a) provide adequate antimicrobial concentration at the target site, (b) offer a slow and constant release of antimicrobial over a prolonged period, and (c) be biodegradable, so that a second operation is not required. 18,19 Various types of bead materials and antibiotics were used based on their ability to achieve a sustained concentration of antibiotic. Poly(lactic acid) is one of the most promising biodegradable biomaterials.…”

Section: Discussionmentioning

confidence: 99%

In vivo release of vancomycin from biodegradable beads

Liu

Ueng

Lin

et al. 2002

J. Biomed. Mater. Res.

View full text Add to dashboard Cite

The current delivery system of antibiotics for the treatment of osteomyelitis uses polymethylmethacrylate (PMMA) beads as a local drug-release agent. The nonbiodegradable nature of the PMMA, however, necessitates a second operation to remove the beads. This article explores the alternative of using biodegradable polymers as antibiotic beads for a long-term drug release in vivo. To manufacture an antibiotic bead, lactide-glycolide copolymers were mixed with vancomycin. The mixture was compressed and sintered at 55 degrees C to form beads 8 mm in diameter. An in vivo animal model was proposed to characterize the elution rate of antibiotic over a 55-day period. Biodegradable beads released high concentrations of antibiotic (well above the breakpoint sensitivity concentration) in vivo for the period of time needed to treat bone infection; that is, 4-6 weeks. A bacterial inhibition test was also carried out to determine the relative activity of the released antibiotics. The diameter of the sample inhibition zone ranged from 8 to 18 mm, which is equivalent to 9.1 to 100% of relative activity. In addition, the antibiotic concentration of systemic blood was found to be very low. Antibiotic-impregnated biodegradable beads may have a potential role in the prevention and management of surgical infections.

show abstract

“…It is known that cells usually 'prefer' hydrophilic surfaces; however, hydrophobic materials have typically longer residence times in vivo (Streubel et al 2000;Malafaya et al 2002), meaning that the selection of the optimal biodegradable polymer for the drug-delivery function in TE scaffolds should be aimed at balancing both aspects. Synthetic biodegradable polymers that have been reported for various drug-eluting devices include PLGA copolymers (Garvin et al 1994;Nie et al 1995;Overbeck et al 1995;Ambrose et al 2003), polycaprolactone (Hendricks et al 2001;Rutledge et al 2003), polyanhydrides (Jacob et al 1991;Nelson et al 1997;Kanellakopoulou & GiamarellosBourboulis 2000;Li, L. C. et al 2002;Li, W. 2002), polyhydroxybutyrate-co-hydroxyvalerate (PHBV) (Yagmurlu et al 1999;Rossi et al 2004) and other polyhydroxyalkanoates (Turesin et al 2001). Natural polymers including proteins such as collagen (Lee et al 2002;Park et al 2004;Sripriya et al 2004;Prabu et al 2006;Shanmugasundaram et al 2006) and polysaccharides such as alginate, hyaluronic acid and chitosan (Muzzarelli et al 1990;Chung et al 1994;Mi et al 2002;Aoyagi et al 2007;Rossi et al 2007) are also attractive, since they exhibit superior biocompatibility and can facilitate cell growth.…”

Section: Polymer Scaffoldsmentioning

confidence: 99%

Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds

Mouriño

Boccaccını

2009

J. R. Soc. Interface.

483

298

View full text Add to dashboard Cite

This paper provides an extensive overview of published studies on the development and applications of three-dimensional bone tissue engineering (TE) scaffolds with potential capability for the controlled delivery of therapeutic drugs. Typical drugs considered include gentamicin and other antibiotics generally used to combat osteomyelitis, as well as anti-inflammatory drugs and bisphosphonates, but delivery of growth factors is not covered in this review. In each case reviewed, special attention has been given to the technology used for controlling the release of the loaded drugs. The possibility of designing multifunctional three-dimensional bone TE scaffolds for the emerging field of bone TE therapeutics is discussed. A detailed summary of drugs included in three-dimensional scaffolds and the several approaches developed to combine bioceramics with various polymeric biomaterials in composites for drug-delivery systems is included. The main results presented in the literature are discussed and the remaining challenges in the field are summarized with suggestions for future research directions.

show abstract

In vitro elution of ofloxacin from a bioabsorbable polymer

Cited by 34 publications

References 17 publications

Efficacy of Ciprofloxacin-Releasing Bioabsorbable Osteoconductive Bone Defect Filler for Treatment of Experimental Osteomyelitis Due to Staphylococcus aureus

Efficacy of Ciprofloxacin-Releasing Bioabsorbable Osteoconductive Bone Defect Filler for Treatment of Experimental Osteomyelitis Due to Staphylococcus aureus

In vivo release of vancomycin from biodegradable beads

Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds

Contact Info

Product

Resources

About